POTELIGEO Drug Insight and Market Forecast - 2032

“POTELIGEO Drug Insight and Market Forecast - 2032” report provides comprehensive insights about POTELIGEO for Cutaneous T-cell lymphoma (CTCL) in the seven major markets. A detailed picture of the POTELIGEO for Cutaneous T-cell lymphoma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy and Spain) and the United Kingdom, and Japan for the study period 2019-2032 is provided in this report along with a detailed description of the POTELIGEO for Cutaneous T-cell lymphoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the POTELIGEO market forecast, analysis for Cutaneous T-cell lymphoma in the 7MM descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Cutaneous T-cell lymphoma.

Drug Summary

POTELIGEO is used to treat adult patients with relapsed or refractory MF or SS after at least one prior systemic therapy. It is marketed in Japan for the treatment of relapsed or refractory CTCL.

Mogamulizumab is a recombinant humanized monoclonal antibody composed of complementarity-determining regions derived from mouse anti-human CC chemokine receptor 4 monoclonal antibody and framework regions and constant regions derived from human IgG1. It is produced in Chinese hamster ovary cells. It is a glycoprotein (molecular weight: ca. 149,000) composed of 2 H chain (γ1- chain) molecules consisting of 449 amino acid residues each and 2 L-chain (κ-chain) molecules consisting of 219 amino acid residues each.

It is a humanized anti-CCR4 defucosylated IgG1 mAb that eliminates tumor cells via ADCC. Using the mechanism, nonspecific effector cells, including natural killer (NK) cells and macrophages/monocytes, possess membrane-bound FcγRs that crosslink with the Fc region of the IgG molecule, bound to a specific target cancer cell, such as the CCR4+ lymphoma cell. FcγR binding increases the activity of the cytotoxic cells, facilitating the release of cytoplasmic lytic enzymes, granzymes, perforin-containing granules, and tumor necrosis factor (TNF) that induce lysis of the antibody-targeted cell.

Dosage and Administration

The recommended dosage of POTELIGEO is 1 mg/kg and is administered as an intravenous infusion over at least 60 minutes. The drug is administered on Days 1, 8, 15, and 22 of the first 28-day cycle, then on Days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity. The drug (POTELIGEO) is administered within 2 days of the scheduled dose. If a dose is missed, administer the next dose as soon as possible and resume the dosing schedule. It is advised not to administer POTELIGEO subcutaneously or by rapid intravenous administration.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the POTELIGEO description, mechanism of action, dosage and administration, research and development activities in Cutaneous T-cell lymphoma.
• Elaborated details on POTELIGEO regulatory milestones and other development activities have been provided in this report.
• The report also highlights the POTELIGEO research and development activity in Cutaneous T-cell lymphoma in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around POTELIGEO.
• The report contains forecasted sales of POTELIGEO for Cutaneous T-cell lymphoma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Cutaneous T-cell lymphoma.
• The report also features the SWOT analysis with analyst views for POTELIGEO in Cutaneous T-cell lymphoma.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

POTELIGEO Analytical Perspective

In-depth POTELIGEO Market Assessment

This report provides a detailed market assessment of POTELIGEO in Cutaneous T-cell lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

POTELIGEO Clinical Assessment

The report provides the clinical trials information of POTELIGEO in Cutaneous T-cell lymphoma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Cutaneous T-cell lymphoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence POTELIGEO dominance.

• Other emerging products for Cutaneous T-cell lymphoma are expected to give tough market competition to POTELIGEO and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of POTELIGEO in Cutaneous T-cell lymphoma.
• The in-depth analysis of the forecasted sales data from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the POTELIGEO in Cutaneous T-cell lymphoma.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of POTELIGEO?
• What is the clinical trial status of the study related to POTELIGEO in Cutaneous T-cell lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the POTELIGEO development?
• What are the key designations that have been granted to POTELIGEO for Cutaneous T-cell lymphoma?
• What is the forecasted market scenario of POTELIGEO for Cutaneous T-cell lymphoma?
• What are the forecasted sales of POTELIGEO in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Cutaneous T-cell lymphoma and how are they giving competition to POTELIGEO for Cutaneous T-cell lymphoma?
• Which are the late-stage emerging therapies under development for the treatment of Cutaneous T-cell lymphoma?

This product will be delivered within 2 business days.